Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Kazanorgsintez recommended that dividends be paid for 2022

5/26/23 KZOS

Shareholders of RPA Nauka approved dividends for 2022

5/26/23 NAUK

Board of Directors of Abrau-Durso recommended that dividends be paid for 3 мес. 2023

5/26/23 ABRD

Board of Directors of Nizhnekamskneftekhim recommended that dividends be paid for 2022

5/26/23 NKNC

Board of Directors of Mosenergo recommended that dividends be paid for 2022

5/26/23 MSNG

Board of Directors of Slavneft-Yaroslavnefteorgsintez recommended that dividends be paid for 2022

5/26/23 JNOS

Sovcomflot reported for 3 months of 2023 by IFRS

5/26/23 FLOT

Renaissance Insurance reports record IFRS profit

5/26/23 RENI

Virgin Galactic successfully conducted the last test flight

5/26/23 SPCE

Severstal maintains capacity utilization, but margins are significantly lower

5/26/23 CHMF